The extent of AICDA-mediated diversity as marked by uBCL2 and IGVH varies widely and is unrelated to the presence of a TP53 mutation. (A) The number of distinct sequences for uBCL2 is the maximum number seen for a single amplicon within that region (refer to Methods). The number of distinct IGVH sequences is the number of distinct variants detected in the clonal IGVH sequence (refer to Methods). Patients with no variants are scored as 1. No relationship is apparent among the number of distinct uBCL2 sequences, the number of distinct IGVH sequences, and the status of TP53 (filled denotes detectable pathogenic lesion; open denotes no detectable lesion). (B-C) No relationship is apparent between the number of variant uBCL2 or IGVH sequences and the time to progression or progression at any time. The number of variant IGVH and uBCL2 sequences was not different between the patients who showed disease progression (blue) or who did not show disease progression (red). Furthermore, there is no suggestion that the number of sequence variants detected differed between those who showed disease progression within 2 years and those who showed disease progression later.